0000950170-23-068277.txt : 20231205 0000950170-23-068277.hdr.sgml : 20231205 20231205171528 ACCESSION NUMBER: 0000950170-23-068277 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231205 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 231467573 BUSINESS ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 8-K 1 olma-20231205.htm 8-K 8-K
0001750284false00017502842023-12-052023-12-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 05, 2023

 

 

Olema Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39712

30-0409740

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

780 Brannan Street

 

San Francisco, California

 

94103

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 651-3316

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

OLMA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 7.01 Regulation FD Disclosure.

On December 5, 2023, Olema Pharmaceuticals, Inc. (the “Company”) announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, interim Phase 2 clinical data of palazestrant in combination with CDK4/6 inhibitor palbociclib, and a trials-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

As described above, on December 5, 2023, the Company announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib, interim Phase 2 clinical data of palazestrant in combination with palbociclib, and a trials-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial. These results will be presented at the San Antonio Breast Cancer Symposium (“SABCS”) at the Henry B. Gonzalez Convention Center in San Antonio, Texas on December 7, 2023.

 

Palazestrant Phase 1b/2 Study in Combination with Ribociclib

 

A poster titled “A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer” will be presented at SABCS. A more recent data cut, as of November 1, 2023, highlights the following:

•
Across 19 patients who had completed at least one cycle of treatment as of the data cutoff date, the combination of up to 120 mg of palazestrant with 600 mg of ribociclib daily was well tolerated, with no safety signals or enhancement of toxicity and an overall safety profile remains consistent with the expected safety profile of ribociclib plus an endocrine therapy.
•
Palazestrant did not affect ribociclib drug exposure in patients, and ribociclib had no clinically meaningful effect on palazestrant drug exposure.
•
There were no dose-limiting toxicities, the maximum tolerated dose was not reached, and the majority of treatment-emergent adverse events were grade 1 or 2, with no grade 4 events observed. Neutropenia was reversible in all patients, and the timing was generally consistent with ribociclib-related neutropenia.
•
Findings from this study support the continued use of palazestrant at the recommended Phase 2 dose of 120 mg in combination with 600mg of ribociclib, and enrollment in the dose-expansion portion of the study is ongoing.

 

The Company anticipates a potential initiation of a Phase 3 clinical trial of palazestrant in combination with ribociclib as early as the end of 2024.

 

Palazestrant Phase 1b/2 Study in Combination with Palbociclib

 

A poster titled “A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients”, will be presented in a Poster Spotlight Session by Prof. Arlene Chan, FRACP, MMed, Breast Cancer Research Centre-WA, Curtin University, Breast Clinical Trials Unit, Hollywood Private Hospital, Nedlands, Australia. The presentation will highlight that:

•
Across 46 patients as of the cutoff date of September 15, 2023, the combination of palazestrant (120 mg) with palbociclib (125 mg) daily was well tolerated, with an overall safety profile consistent with the expected safety profile of palbociclib plus an endocrine therapy.
•
There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination. Most treatment-emergent adverse events were grade 1 or 2. Neutropenia incidence was similar to the PALOMA-3 study; it was reversible in all patients and the timing was generally consistent with the palbociclib-related neutropenia.
•
Tumor responses and prolonged disease stabilization were observed in this patient group, including in those previously exposed to CDK4/6 inhibitors, in both ESR1 mutant and ESR1 wild-type tumors. Partial responses were observed in seven patients, with two confirmed partial responses and five unconfirmed partial responses. The clinical benefit rate was
46% in all patients and 60% in patients with an ESR1 mutation at baseline. In patients naïve to prior CDK4/6 inhibitor treatment, the CBR was 71%. 53% of patients had any reduction in target lesion size.
•
Twenty-two (48%) patients remain on treatment, and efficacy data are still maturing. Findings from this study are consistent with previously reported data and support the ongoing clinical development of palazestrant in combination with CDK4/6 inhibitors for the treatment of ER+/HER2− metastatic breast cancer.

 

OPERA-01 Phase 3 Monotherapy Trial

 

Olema will present a poster titled “OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy”, that details the ongoing clinical trial design, inclusion/exclusion criteria, and trial endpoints.

 

Forward Looking Statements

 

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “expect,” “will,” “may,” “goal,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics, safety, tolerability, efficacy, and therapeutic effects of palazestrant, the development of palazestrant, the initiation and timing of clinical trials, and palazestrant’s combinability with other drugs. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press Release, dated December 5, 2023, of Olema Pharmaceuticals, Inc.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Olema Pharmaceuticals, Inc.

 

 

 

 

Date:

December 5, 2023

By:

/s/ Shane Kovacs

 

 

 

Shane Kovacs
Chief Operating and Financial Officer

 

 EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

 

•
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapy
•
OPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023
•
Olema will host an investor conference call at 8:00 a.m. ET on December 6, 2023

 

SAN FRANCISCO, December 5, 2023 – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on interim Phase 2 clinical data of palazestrant in combination with palbociclib, and a trials-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This disclosure was originally planned for December 7, 2023. However, on December 5, 2023, the 2023 San Antonio Breast Cancer Symposium (SABCS) published the posters ahead of schedule. These full data are scheduled to be presented on December 7, 2023, and copy of the posters are available now on Olema’s website under the Science section.

“We believe the results we are presenting at SABCS demonstrate that palazestrant has key characteristics that make it a potential best-in-class endocrine therapy for ER+/HER2- breast cancer: complete antagonism of the estrogen receptor, favorable tolerability and tumor response, and attractive combinability with CDK4/6 inhibitors,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “OPERA-01, our Phase 3 monotherapy pivotal trial of palazestrant, has initiated, with multiple trial sites now activated and patient dosing started. The data we are gathering in our Phase 2 combination studies with CDK4/6 inhibitors, ribociclib and palbociclib, support the potential initiation of a pivotal first-line combination trial as early as the end of 2024, bringing us closer to achieving our goal of transforming the standard of care for women’s cancers.”

Palazestrant Phase 1b/2 Study in Combination with Ribociclib: A poster titled “A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer” will be presented at SABCS. A more recent data cut, as of November 1, 2023, highlights the following:

•
Across 19 patients who had completed at least one cycle of treatment as of the data cutoff date, the combination of up to 120 mg of palazestrant with 600 mg of ribociclib

 

 

 

daily was well tolerated, with no safety signals or enhancement of toxicity and an overall safety profile remains consistent with the expected safety profile of ribociclib plus an endocrine therapy.
•
Palazestrant did not affect ribociclib drug exposure in patients, and ribociclib had no clinically meaningful effect on palazestrant drug exposure.
•
There were no dose-limiting toxicities, the maximum tolerated dose was not reached, and the majority of treatment-emergent adverse events were grade 1 or 2, with no grade 4 events observed. Neutropenia was reversible in all patients, and the timing was generally consistent with ribociclib-related neutropenia.
•
Findings from this study support the continued use of palazestrant at the recommended Phase 2 dose of 120 mg in combination with 600mg of ribociclib, and enrollment in the dose-expansion portion of the study is ongoing.

 

Palazestrant Phase 1b/2 Study in Combination with Palbociclib: A poster titled “A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients”, will be presented in a Poster Spotlight Session by Prof. Arlene Chan, FRACP, MMed, Breast Cancer Research Centre-WA, Curtin University, Breast Clinical Trials Unit, Hollywood Private Hospital, Nedlands, Australia. The presentation will highlight that:

•
Across 46 patients as of the cutoff date of September 15, 2023, the combination of palazestrant (120 mg) with palbociclib (125 mg) daily was well tolerated, with an overall safety profile consistent with the expected safety profile of palbociclib plus an endocrine therapy.
•
There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination. Most treatment-emergent adverse events were grade 1 or 2. Neutropenia incidence was similar to the PALOMA-3 study; it was reversible in all patients and the timing was generally consistent with the palbociclib-related neutropenia.
•
Tumor responses and prolonged disease stabilization were observed in this patient group, including in those previously exposed to CDK4/6 inhibitors, in both ESR1 mutant and ESR1 wild-type tumors. Partial responses were observed in seven patients, with two confirmed partial responses and five unconfirmed partial responses. The clinical benefit rate was 46% in all patients and 60% in patients with an ESR1 mutation at baseline. In patients naïve to prior CDK4/6 inhibitor treatment, the CBR was 71%. 53% of patients had any reduction in target lesion size.
•
Twenty-two (48%) patients remain on treatment, and efficacy data are still maturing. Findings from this study are consistent with previously reported data and support the ongoing clinical development of palazestrant in combination with CDK4/6 inhibitors for the treatment of ER+/HER2− metastatic breast cancer.

 

 

 

 

OPERA-01 Phase 3 Monotherapy Trial: Olema will present a poster titled “OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy”, that detailed the ongoing clinical trial design, inclusion/exclusion criteria, and trial endpoints. Please find more details at www.opera-01.com or at clinicaltrials.gov (NCT06016738).

 

Company Investor Webcast and Conference Call

Olema will host a webcast and conference call for analysts and investors to review data presented at SABCS 2023 as well as other ongoing studies tomorrow, Wednesday, December 6, 2023, at 8:00 a.m. ET (7:00 a.m. CT). Please register for the webcast by visiting the Investors & Media section of Olema’s website at olema.com.

 

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 3 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “expect,” “will,” “may,” “goal,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics, safety, tolerability, efficacy, and therapeutic effects of palazestrant, the development of palazestrant, the initiation and timing of clinical trials, palazestrant’s combinability with other drugs, the potential of palazestrant to become a best-in-class endocrine therapy in the treatment of ER+/HER2- metastatic breast cancer or transform the standard of care treatments for women living with ER+/HER2- metastatic breast cancer. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These

 

 

 

forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

 

# # #

 

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications

ir@olema.com

 

 

 

 

 EX-101.LAB 3 olma-20231205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 olma-20231205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 olma-20231205.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Dec. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 05, 2023
Entity Registrant Name Olema Pharmaceuticals, Inc.
Entity Central Index Key 0001750284
Entity Emerging Growth Company false
Entity File Number 001-39712
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 30-0409740
Entity Address, Address Line One 780 Brannan Street
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94103
City Area Code 415
Local Phone Number 651-3316
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol OLMA
Security Exchange Name NASDAQ
XML 7 olma-20231205_htm.xml IDEA: XBRL DOCUMENT 0001750284 2023-12-05 2023-12-05 0001750284 false 8-K 2023-12-05 Olema Pharmaceuticals, Inc. DE 001-39712 30-0409740 780 Brannan Street San Francisco CA 94103 415 651-3316 N/A false false false false Common Stock, par value $0.0001 per share OLMA NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports olma-20231205.htm olma-20231205.xsd olma-20231205_lab.xml olma-20231205_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "olma-20231205.htm": { "nsprefix": "olma", "nsuri": "http://olema.com/20231205", "dts": { "inline": { "local": [ "olma-20231205.htm" ] }, "schema": { "local": [ "olma-20231205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "olma-20231205_lab.xml" ] }, "presentationLink": { "local": [ "olma-20231205_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ed2c451e-14e0-4d58-b5d0-a865dad28c05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "olma-20231205.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ed2c451e-14e0-4d58-b5d0-a865dad28c05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "olma-20231205.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://olema.com/20231205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-23-068277-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-068277-xbrl.zip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end